ENTX (Entera Bio) Other Current Liabilities: $0.45 Mil (As of Mar. 2026)


ENTX Entera Bio Ltd ENTX
23 GF Score
Price $1.70
! 2 Warning Signs
View Full Analysis

What is Entera Bio Other Current Liabilities?

Entera Bio ENTX +0.59% 23 Other Current Liabilities is $0.45 Mil as of Mar. 2026. GuruFocus rates ENTX with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

Entera Bio's other current liabilities for the quarter that ended in Mar. 2026 was $0.45 Mil.

Entera Bio's quarterly other current liabilities declined from Sep. 2025 ($0.50 Mil) to Dec. 2025 ($0.43 Mil) but then increased from Dec. 2025 ($0.43 Mil) to Mar. 2026 ($0.45 Mil).

Entera Bio's annual other current liabilities declined from Dec. 2023 ($0.37 Mil) to Dec. 2024 ($0.34 Mil) but then increased from Dec. 2024 ($0.34 Mil) to Dec. 2025 ($0.43 Mil).

Entera Bio Other Current Liabilities Related Terms

Entera Bio Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Entera Bio's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entera Bio Other Current Liabilities Chart

Entera Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.46 0.30 0.37 0.34 0.43

Entera Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.56 0.50 0.43 0.45
ENTX
23GF Score
Entera Bio Ltd ENTX
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Entera Bio Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $0.45 Mil mean?
Entera Bio (ENTX) has a Other Current Liabilities of $0.45 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Entera Bio.
Is Entera Bio's Other Current Liabilities too high?
Entera Bio's current Other Current Liabilities is $0.45 Mil. Overall, Entera Bio has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Entera Bio's Other Current Liabilities compare to HRTX and OKYO?
Entera Bio's Other Current Liabilities of $0.45 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Entera Bio. Entera Bio's current Other Current Liabilities is $0.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entera Bio stock overvalued right now?
Entera Bio (ENTX) has a current Other Current Liabilities of $0.45 Mil. The current Other Current Liabilities is $0.45 Mil. Entera Bio's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Entera Bio (ENTX), the current Other Current Liabilities is $0.45 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entera Bio Business Description

Other Exchanges 5DT:Germany
Address Kiryat Hadassah, Minrav Building - Fifth Floor, Hadassah Bio Park, Jerusalem, ISR, 9112002
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
23GF Score

Get the complete analysis for ENTX

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.70
Price